top of page

IRA side effect: Pharma companies will increasingly skip Medicare altogether, Lilly CEO says


As the Centers for Medicare and Medicaid Services races to finalize guidance on how it will negotiate — or dictate, depending on if you ask a pharma exec — the prices of the costliest medicines in the US, pharma execs are warning of unwanted repercussions...



Comments


bottom of page